Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 104

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 104
---
certain warrant inducement agreements, we issued an aggregate of 12,417 Depositary Shares to certain holders of our Series E Warrants
and Series F Warrants, upon the exercise of 6,290 Series E Warrants and 6,127 Series F Warrants, at an exercise price of $375.00 per
share. In addition, we issued to such holders an aggregate of 9,434 Series G Warrants, and 14,780 Series H Warrants. The aggregate gross
proceeds to the Company were approximately $6.05 million, before deducting agent fees and expenses. Additionally, we issued warrants
to purchase 644 of our Depositary Shares in connection with the offering to Ladenburg, as agent, and certain designees of Ladenburg.

| 54 |

On July 22, 2024, in a private placement, we issued and sold (x) Series J Warrants exercisable for 21,315 Depositary Shares, and (y) Series K Warrants to purchase an aggregate of 21,315 Depositary Shares. The warrants are immediately exercisable at an exercise price of $250.00 per Depositary Share, subject to adjustments for certain dilutive equity issuances. The aggregate gross proceeds to the Company were approximately $5.0 million (including shares sold in a concurrent registered direct offering). Additionally, we issued warrants to purchase 851 of our Depositary Shares in connection with the offering to Ladenburg, as the placement agent in the offering, and certain of its designees.

On May 15, 2025, we entered into letter
agreements with certain accredited holders of our outstanding Series E Warrants, Series H Warrants, Series J Warrants, and Series K Warrants,
issued in prior transactions, pursuant to which the such holders agreed to exercise certain of such warrants in exchange for a reduction
in exercise price of each warrant to $3.10 per share. An aggregate of 20,041 warrants were exercised for aggregate gross proceeds of
approximately $62,000, before estimate offering expenses. We did not issue new warrants to replace the warrants that were exercised.

| Item 8. | Exhibits and Financial Statement Schedules |

(a) The Exhibit
Index is incorporated herein by reference.

See the Exhibit Index attached
to this registration statement, which is incorporated herein by reference.

(b) Financial
Statement Schedules.

Schedules not listed above
have been omitted because the information required to be set forth therein is not